Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (511)	5/14/2003 2:29:59 PM
From: tuck	Read Replies (1) \| Respond to of 897

I grant you price doesn't matter for approval, though it certainly matters for marketing. I would think that for Xolair, an asthma drug, the safety bar would be very high. Look at SEPR. A little hint of qtc prolongation and down it went. Although Enbrel and Remicade are approved for somewhat cosmetic conditions (in addition to more serious ones), they are conditions that currently are not easy to manage. Asthma is manageable, with much cheaper drugs with established safety records. IMO, and I'd love further input. Cheers, Tuck